Information Library
Case Studies - Business transformation
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Enabling Transformation
September 30, 2009
Biovitrum found an ideal opportunity to transform itself into a fully integrated specialty pharmaceutical company from a biotech discovery and early clinical development company. -
Exceeding expectations
August 13, 2009
Discover how the scale of some marketing challenges stretches even the most powerful companies. -
Making the Most of a Smart Move
March 26, 2009
In late 2007, Scotland-based ProStrakan Group plc seemed to have everything going for it: four new European product introductions planned for an 18-month period and near-term product launches with an aggregate peak sales potential of $400 to $500 million, both backed by a 340-person pan-European salesforce. -
Grabbing a Leadership Position
March 26, 2009
Astellas-NovaQuest Alliance Establishes Market Leadership Platform for Vesicare -
Driving Near Term Sales & Savings
March 26, 2009
NovaQuest’s predecessor, PharmaBio Development, funded a dedicated sales force of 150 experienced Innovex cardiovascular representatives for two years, in return for a five-year royalty on the net sales of Advicor and its predecessor product, Niaspan®. PharmaBio also received warrants to purchase shares of Kos Pharmaceuticals stock. -
How to Keep All Your Licenses in Compliance
March 25, 2009
Our customer had a series of pharmaceutical and biological products that had been on the market in various countries for 10 years or more. They made a number of manufacturing improvements, and they needed to update their myriad licenses. -
Gain Capital & Retain Value
March 24, 2009
Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product.
Page 1 of 1 (7 items)